Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.
Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Ronald Martell |
Contact Details
Address: 2200 Bridge Pkwy, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650 549 1400 |
| Website | jaspertx.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001788028 |
| CUSIP Number | 471871103 |
| ISIN Number | US4718712023 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald A. Martell | President, Chief Executive Officer and Director |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board and Director |
| Herbert C. Cross CPA | Chief Financial Officer and Corporate Secretary |
| Jeetinder Singh Mahal M.B.A. | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | SCHEDULE 13G | Filing |
| Jul 17, 2025 | SCHEDULE 13G/A | Filing |
| Jul 11, 2025 | SCHEDULE 13G | Filing |
| Jul 9, 2025 | 8-K | Current Report |
| Jul 7, 2025 | 8-K | Current Report |
| Jul 3, 2025 | 8-K | Current Report |
| Jun 16, 2025 | 8-K | Current Report |
| May 19, 2025 | ARS | Filing |